ALLMedicine™ Blastic Plasmacytoid Dendritic Cell Center
Research & Reviews 191 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051102
Nature Communications; Cai T, Gouble A et. al.
Apr 29th, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially ...
https://doi.org/10.1182/bloodadvances.2021006306
Blood Advances; Rethnam M, Tan DQ et. al.
Apr 29th, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with poor clinical outcomes. Dysregulated MYC expression, which is associated with protein arginine methyltransferase 5 (PRMT5) dependency, is a r...
https://doi.org/10.3324/haematol.2022.280843
Haematologica Vangala DB, Nilius-Eliliwi V et. al.
Apr 8th, 2022 - Not available.
https://doi.org/10.1182/blood.2021015236
Blood Yu YT, Chang KC
Apr 8th, 2022 - Immunoblastoid blastic plasmacytoid dendritic cell neoplasm with MYC rearrangement.|2022|Yu YT,Chang KC,|genetics,
https://doi.org/10.1038/s41375-022-01538-9 10.1038/s41590-018-0136-9 10.1182/blood.V97.10.3210 10.1016/j.bbmt.2016.03.022 10.3390/cancers11050595 10.1038/leu.2014.64 10.1097/PAS.0b013e3181c5e26b 10.3324/haematol.2012.072645 10.1186/s13039-016-0232-1 10.1182/blood.V99.11.4154 10.1002/ajh.23567 10.18632/oncotarget.2223 10.1038/leu.2013.283 10.1111/bjh.14146 10.1038/s41375-021-01228-y 10.1038/leu.2017.38 10.1038/s41408-018-0120-5 10.3324/haematol.2020.247569 10.1097/PAS.0000000000001316 10.1111/bjh.17347 10.3324/haematol.2013.093765 10.1038/s41467-020-19119-8 10.1038/gim.2015.30 10.1038/s41375-018-0150-9 10.1056/NEJMoa1408617 10.1038/s41586-020-2819-2 10.1182/blood-2016-05-714030 10.1200/JCO.2012.47.3314 10.1080/10428194.2021.1924372 10.1038/leu.2015.337 10.1182/blood-2015-03-631747 10.1007/s12185-020-03070-x 10.1056/NEJMoa1815105
Leukemia Khanlari M, Yin CC et. al.
Mar 14th, 2022 - Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are reported in up to 20% patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), where a shared clonal origin is shown in individual case studies. In this study...
Drugs 2 results see all →
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT02623439
Oct 14th, 2020 - Study Design: This is a single center Phase 2 study of myeloablative (MA) and nonmyeloablative (NMA) conditioning, transplantation of partially HLA-mismatched bone marrow or peripheral blood stem cells and post-transplantation cyclophosphamide (Cy...
https://clinicaltrials.gov/ct2/show/NCT02859623
Aug 9th, 2016 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected orga...
News 34 results
https://www.mdedge.com/dermatology/article/252525/dermatopathology/isolated-nodule-and-generalized-lymphadenopathy
Yahya Daneshbod, MD, Michael Greas, MD et. al.
Mar 8th, 2022 - The Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm A diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was rendered. Subsequent needle core biopsy of a left axillary lymph node as well as bone marrow aspiration and biopsy.
https://www.onclive.com/view/tagraxofusp-and-hyper-cvad-represent-treatment-options-for-patients-with-bpdcn
Feb 3rd, 2022 - Despite the rarity of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2 studies examining treatment options for the disease produced encouraging results and safety data, according to Naveen Pemmaraju, MD. Pemmaraju p...
https://www.onclive.com/view/dr-pemmaraju-on-the-ongoing-trial-of-tagraxofusp-in-myelofibrosis
Oct 6th, 2021 - Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermedia...
https://www.onclive.com/view/dr-pemmaraju-on-the-trial-of-sl401-in-blastic-plasmacytoid-dendritic-cell-neoplasms
Oct 6th, 2021 - Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms (BPDCL). SL-401 is a novel agent under in...
https://www.mdedge.com/dermatology/article/246549/rare-diseases/rare-hematologic-malignancy-may-first-present-dermatologist
Doug Brunk
Sep 23rd, 2021 - Dermatologists may be the first clinicians to diagnose blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive hematologic malignancy that involves the skin in about 80% of cases. Courtesy Dr.
